Impact of the Annex 1 Revision on Pharmaceutical Water
Recommendation
28/29 January 2025
Generation, Monitoring & Compliance
The long-awaited draft of the new Annex 1 was published in December 2017. Besides mainly contents concerning sterile production, it also contains various updates on the manufacturing and distribution of water to be used in pharmaceutical production.
In the new Annex 1, pharmaceutical water has gained its own subsection with altogether 10 paragraphs (7.7 to 7.16). The currently applicable Annex 1 contains only two: 59 & 72.
A significant update is the reference to cold WFI (water for injection) and WFI produced by non-distillation methods. Since April 2017, the European Pharmacopoeia has been permitting the production of WFI by methods other than distillation. After the EMA published a Q&A paper on this issue in summer 2017, the expectations were high for the Annex 1 draft since the EMA paper left several major questions unanswered. Sadly, the new Annex 1 draft does not rectify that fact. However, nanofiltration and ultrafiltration are named as purification steps after the final RO membrane. Reverse osmosis alone therefore seems to be considered insufficient as a purification step.
The general requirement for water systems to be designed in a way that minimises the risk of a microbial contamination has remained the same. Water systems must be validated; what is new is the explicit requirement for consideration of seasonal influences. This, however, has been state of the art for many years and is covered by the three phase model for validating a water system (see FDA - "Inspection of High Purity Water Systems").
Other new additions are the requirement for turbulent water flow (7.10) and notes on avoiding dead legs as well as on the sloping of piping (7.11). A note about vent filters, a frequent point of discussion during inspections, can now be found in 7.12.
The requirement for a "worst case" sample point is also worth mentioning. In general, all sampling points should be considered in the sampling plan. The so-called worst case sample point, e.g. at the end of a distribution loop return, is to be sampled every time water is extracted for manufacturing. The explicit requirement for continuous monitoring ("Total Organic Carbon" (TOC) or conductivity) for all WFI systems is also new. Up to now, this was also possible offline (through sampling).
On the EU Commission's official website you will find the complete Annex 1 draft.
Related GMP News
11.12.2024Warning Letter to Indian Manufacturer of Sterile Ophthalmic Drop Products
06.11.2024FDA Warning Letter to a US Manufacturer of Medical Gases
30.10.2024WHO Guidance on Wastewater and Solid Waste Treatment in the Antibiotics Production
23.10.2024Warning Letter to Indian sterile Manufacturer due to Cross-Contamination and Particles
16.10.2024Do Parenterals have to be 100% free of Particles?
02.10.2024Does Purified Water have to be tested for Endotoxins?